Navigation Links
The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
Date:8/21/2007

g, improve its international standing. Canada Economic Development's financial participation in an initiative that holds so much promise for the economic diversification of the region is entirely consistent with the new science and technology strategy Canada has put in place to, among other things, strengthen the ties between entrepreneurs and scientists. It is a good illustration of the determination of Canada's new government to adopt principles and policies that will set the stage for economic growth and new business opportunities," stated Minister Blackburn.

Minister Bachand sees this new research infrastructure as the realization of an innovative resource solidly integrated in an international genome research project. "This new scientific infrastructure is strategic for Quebec. It demonstrates our government's desire to support innovation and excellence anywhere it develops. With this investment, we are laying a foundation on the genomics expertise developed here, in the Saguenay-Lac Saint-Jean, to build the innovative, prosperous Quebec we want for future generations."

The Biobank is Genome Quebec's fourth platform. "This is part of the implementation of our business model, which aims to group advanced equipment financed by major projects in genomics and increase its availability to academic and private sector scientists. This way, using the expertise developed in the Saguenay-Lac Saint-Jean, we will help create a formative research tool in Quebec that, thanks to the ties created through CARTaGENE and the P3G international consortium, will become part of a network of major international biobanks that contribute to significant advances in science," said Mr. Paul L'Archeveque, President and CEO of Genome Quebec.

Dr. Richard Lemieux, Executive Director of the Centre de sante et de services sociaux de Chicoutimi, was pleased with the announcement and highlighted the scientific contribution of Dr. Daniel Gaudet's team in the design of the Biobank.
'/>"/>

SOURCE GenVault
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Digital Government Summit seeks to bridge the digital divide
2. Midwest telecom conference to push government cooperation
3. State IT leaders make Government Technologys top-25 list
4. Human cloning plans get blessing from British government
5. State CIO wants to unify electronic government
6. State CIO discusses IT and government
7. Upcoming technology conferences look at government tech and RFID issues
8. Wisconsin technology companies awarded over $24 million in government funding
9. Muskego Powers Local Governments Web Site and Search Capabilities
10. Wisconsin to Get Serious about E-Government
11. SBIR/STTR Programs: Free Money or an Invitation to Governmental Bureaucracy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... the development and commercialization of a once-daily, oral therapy ... today announced financial results for the period ended June ... , Reported cash and cash equivalents totaling $37.4 ... December 31, 2013.  , Reported a net loss ...
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... in China , today announced that it ... ended June 30, 2014, after market close on Thursday, August ... prior to the market opening on Friday, August 15, 2014, ... p.m. China Standard Time) to review the Company,s financial results ...
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... -- ECC West Africa, LLC (ECC) signed a contract in ... Hospital (UCH) Ibadan Board of Management for the first ... and operate and maintain a new, state-of-the-art Cancer Institute ... first of the 4-phase project, ECC will conduct feasibility ... Ibadan intends to finance and develop the Cancer Institute ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... LAFAYETTE, Ind. - Researchers are creating a system that ... reducing a car,s fuel consumption. The effort is ... National Science Foundation and the U.S. Department of Energy. ... which is developing a prototype using thermoelectric generators, or ...
... 2010 Crescent Healthcare today announced a planned expansion ... a lease to open an infusion pharmacy in Totowa, ... services to current patients in Massachusetts, Maryland, New York, ... Rhode Island. In addition to supporting ...
... Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results ...
Cached Biology Technology:Technology uses auto exhaust heat to create electricity, boost mileage 2Technology uses auto exhaust heat to create electricity, boost mileage 3Crescent Healthcare Expands East Coast Presence 2Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 2Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 3Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 4Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 5Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 6Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 7Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 8Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 9Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 10
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... , Washington, D.C. (October 5, 2010) -- The explosion ... such as cell and smart phones, Bluetooth hands-free units, ... from the development of a wide variety of integrated ... on which the communication is based. Continuing ...
... nanotubes -- long, hollow cylinders of carbon billionths of ... in nanotechnology, optics, electronics, and many other fields. The ... scientists as yet have little control over that structure, ... growth -- of the nanotubes. In fact, says chemical ...
... A research team from the University of British Columbia and ... Hospital has identified the role of a type of T ... treatment options for young patients. Also known as juvenile ... children and young adults. In patients with type 1 diabetes, ...
Cached Biology News:The effects of hydrogen on growing carbon nanotubes 2
EZ-Tn5™ Transposase is designed for use with our pMOD™ series of vectors as well as any EZ-Tn5™ transposon system....
... PBL's bioassays for interferons are cytopathic effect ... assays. Sample types include; tissue culture supernatents; ... In these assays, one unit is defined as ... reduce the cytopathic effect of viral infection by ...
HyPro 100, includes 5 x HyPro20 and HyPro Cabinet. 100 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
Biology Products: